Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Stapokibart vs Oral Corticosteroids in Chronic Rhinosinusitis with Nasal Polyps and Allergic Disease
ChiCTR2600127373Phase 4Not yet recruiting
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP) and allergy (2 arms), sponsored by Shenzhen Nanshan People's Hospital. Primary endpoints: Nasal Polyp Score (NPS), Intraoperative blood loss and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)allergy
Beyond the preview
Go deeper on ChiCTR2600127373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127373.